Azenta, Inc. (BA3)
XDUS 
Summary
BA3 Chart
Allspring Common Stock Fund: Q1 2026 Top Contributors And Detractors
Health care was the most significant detractor, led by weakness within life sciences tools and services, while consumer discretionary and IT also weighed on relative performance. Regal Rexnord Corp. performed strongly in the first quarter, primarily on account of a quarterly report that featured particularly strong orders owing to budding demand for data center products. Westlake Corp. outperformed in the first quarter due to the effects on global chemical markets from the conflict in Iran, which has had an extreme impact on supply.
Azenta: Life Science Player Fails To Come To Life
Azenta, Inc. trades near $20, with operating assets valued at just 0.5x sales and a robust net cash position around $600 million. Recent AZTA developments include the UK Biocentre acquisition and B Medical Systems divestiture, with the latter removing a key earnings drag. Despite a soft Q1 and margin pressure, Azenta maintains full-year guidance, supported by remediation efforts and interest income.
Azenta, Inc. (AZTA) M&A Call Transcript
Azenta, Inc. (AZTA) M&A Call Transcript
Azenta, Inc. (BA3) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Azenta, Inc. ever had a stock split?
Azenta, Inc. Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | John Marotta CEO | XDUS Exchange | US1143401024 ISIN |
| US Country | 3,000 Employees | 2 Dec 2021 Last Dividend | - Last Split | - IPO Date |
Overview
Azenta, Inc. offers specialized biological and chemical compound sample management and exploration solutions tailored for the life sciences market globally, including regions such as North America, Africa, China, the United Kingdom, the rest of Europe, and the Asia Pacific. With operations in two key segments - Life Sciences Products and Life Sciences Services - Azenta caters to a wide audience in pharmaceuticals, biotech, healthcare, clinical research, and academic sectors. It has transformed from its original name, Brooks Automation, Inc., reflecting its focus and expertise in life sciences since its establishment in 1978. Based in Burlington, Massachusetts, Azenta has evolved to become a pivotal provider of comprehensive services and products for managing, preserving, and analyzing biological samples and compounds for the life sciences industry.
Products and Services
- Automated Cold Storage Solutions
These include advanced storage facilities designed to automate the management of samples at cold temperatures, ensuring their preservation and integrity for long-term research and analysis needs.
- Consumables and Instruments
A wide range of essential laboratory consumables and instruments, including vials, tubes, polymerase chain reaction plates, and devices supporting various workflows, all tailored to enhance the efficiency of life sciences research.
- Controlled Rate Thawing Devices
Specially designed devices for the controlled thawing of frozen samples to preserve their biological activity and integrity for further analysis or experimentation.
- Temperature-Controlled Storage and Transportation Solutions
Offers a suite of solutions for the storage and transport of temperature-sensitive samples, ensuring they remain uncompromised throughout their journey and storage period.
- Genomic Services
Comprehensive genomic analysis offerings, including gene sequencing and synthesis services that support the research, discovery, and development processes in life sciences.
- Sample Repository Solutions
Services encompassing both on-site and off-site sample storage, cold chain logistics, sample transport, collection relocation, bio-processing solutions, and disaster recovery. Azenta also provides project management and consulting services, underscoring its role as a versatile partner in biospecimen management.
- Biospecimen Procurement Services
Reliable procurement of biospecimens tailored to the specific needs of research, development, and clinical studies, facilitating advancements in healthcare and biotechnology.
